|
95
|
260
|
7u8sA |
Crystal structure of kpc-2 with compound 2 |
|
75
|
228
|
7up3A |
Ndm1-inhibitor co-structure |
|
78
|
229
|
7uoyA |
Ndm1-inhibitor co-structure |
|
82
|
241
|
7uoxA |
Ndm1-inhibitor co-structure |
|
80
|
241
|
7up1A |
Ndm1-inhibitor co-structure |
|
71
|
230
|
7up2A |
Ndm1-inhibitor co-structure |
|
258
|
778
|
8e3jA |
Co-crystal structure of chaetomium glucosidase with compound 4 |
|
267
|
778
|
8e3pA |
Co-crystal structure of chaetomium glucosidase with compound 5 |
|
95
|
315
|
8g62A |
Papain-like protease of sars cov-2 in complex with remodilin ncgc 390004 |
|
107
|
377
|
7tuoA |
Crystal structure analysis of human usp28 complex with a compound |
|
124
|
313
|
5se6A |
Crystal structure of human phosphodiesterase 10 in complex with 2,9-dimethyl-6-[(1-methyl-4-phenylimidazol-2-yl)methoxy]purine |
|
125
|
313
|
5sehA |
Crystal structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide |
|
126
|
312
|
5se8A |
Crystal structure of human phosphodiesterase 10 in complex with 4-(azetidine-1-carbonyl)-2-methyl-n-[2-(2-methyl-5-phenyl-1,2,4-triazol-3-yl)ethyl]pyrazole-3-carboxamide |
|
344
|
889
|
8ewzA |
Plasmodium falciparum m1 in complex with inhibitor 9c |
|
335
|
888
|
8eyfA |
Plasmodium falciparum m1 in complex with inhibitor 15aa |
|
343
|
890
|
8ez2A |
Plasmodium falciparum m1 in complex with inhibitor 15ag |
|
336
|
888
|
8eydA |
Plasmodium falciparum m1 in complex with inhibitor 15ah |
|
345
|
889
|
8ex3A |
Plasmodium falciparum m1 in complex with inhibitor 9aa |
|
334
|
889
|
8eyeA |
Plasmodium falciparum m1 in complex with inhibitor 9aj |
|
163
|
613
|
7svpA |
Structure of compound 34 bound to human phospholipase d2 catalytic domain |
|
179
|
519
|
8ez4A |
Plasmodium falciparum m17 in complex with inhibitor 9aa |
|
85
|
287
|
7t4jA |
Crystal structure of egfr_d770_n771insnpg/v948r in complex with tak-788 |
|
88
|
261
|
7y4kA |
Crystal structure of ricin a chain bound with n2-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycyl-l-phenylalanyl-n6-((benzyloxy)carbonyl)-l-ornitine |
|
17
|
99
|
7masA |
Drug resistant hiv-1 protease (l10f, m46i, i50v, f53l, l63p, g73s) in complex with drv |
|
18
|
99
|
7maaA |
Hiv-1 protease (i84v) in complex with umass10 |
|
18
|
99
|
7ma8A |
Hiv-1 protease (i84v) in complex with umass8 |
|
18
|
99
|
7ma6A |
Hiv-1 protease (i84v) in complex with umass5 |
|
18
|
99
|
7ma4A |
Hiv-1 protease (i84v) in complex with umass3 |
|
18
|
99
|
7maqA |
Drug resistant hiv-1 protease (l10f, v32i, l33f, k45i, a71v, v82i, i84v) in complex with drv |
|
18
|
99
|
7ma7A |
Hiv-1 protease (i84v) in complex with umass7 |
|
17
|
99
|
7marA |
Drug resistant hiv-1 protease (l10f, m46i, i47v, i50v, f53l, l63p, i72v, g73s, v82i, i85v) in complex with drv |
|
18
|
99
|
7ma5A |
Hiv-1 protease (i84v) in complex with umass4 |
|
18
|
99
|
7ma3A |
Hiv-1 protease (i84v) in complex with umass2 |
|
18
|
99
|
7mapA |
Drug resistant hiv-1 protease (l10i, v32i, l33f, k45i, m46i, i50v, a71v, v82i, i84v) in complex with drv |
|
18
|
99
|
7ma9A |
Hiv-1 protease (i84v) in complex with umass9 |
|
54
|
228
|
8dg6A |
Scaffold hopping via ring opening enables identification of acyclic compounds as new complement factor d inhibitors |
|
54
|
230
|
8deaA |
Scaffold hopping via ring opening enables identification of acyclic compounds as new complement factor d inhibitors |
|
51
|
230
|
8d95A |
Scaffold hopping via ring opening enables identification of acyclic compounds as new complement factor d inhibitors |
|
127
|
313
|
5skgA |
Crystal structure of human phosphodiesterase 10 in complex with 2-chloro-6-(cyclopropylamino)-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyridine-4-carboxamide |
|
126
|
313
|
5skhA |
Crystal structure of human phosphodiesterase 10 in complex with 3-[2-(3-fluorophenyl)pyrazol-3-yl]-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one |
|
121
|
313
|
5skiA |
Crystal structure of human phosphodiesterase 10 in complex with n-[(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl]-2-methyl-5-phenyl-1,2,4-triazol-3-amine |
|
126
|
313
|
5skjA |
Crystal structure of human phosphodiesterase 10 in complex with 6-cyclopropyl-n-[2-[2-(methylamino)-2-oxoethyl]phenyl]-3-(pyrimidin-5-ylamino)pyridine-2-carboxamide |
|
78
|
302
|
7mb0A |
Sars-cov-2 main protease (mpro) in complex with covalent inhibitor sm141 |
|
125
|
313
|
5sepA |
Crystal structure of human phosphodiesterase 10 in complex with 2-[2-(4-cyclopentyl-1-methylimidazol-2-yl)ethyl]-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine |
|
128
|
315
|
5shrB |
Crystal structure of human phosphodiesterase 10 in complex with n-[(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)methyl]-n,2-dimethyl-5-phenyl-1,2,4-triazol-3-amine |
|
127
|
313
|
5sfeA |
Crystal structure of human phosphodiesterase 10 in complex with 3-n-[2-(3-fluorophenyl)imidazo[1,2-a]pyrimidin-7-yl]-4-n,4-n,2-trimethylpyrazole-3,4-dicarboxamide |
|
127
|
313
|
5skmA |
Crystal structure of human phosphodiesterase 10 in complex with 6-chloro-n,n-dimethyl-2-[2-(1-pyridin-2-ylpyrrolidin-3-yl)ethyl]quinazolin-4-amine |
|
80
|
304
|
7mb1A |
Sars-cov-2 main protease (mpro) in complex with covalent inhibitor sm143 |
|
77
|
305
|
7mb3A |
Sars-cov-2 main protease (mpro) in complex with covalent inhibitor sm145 |
|
124
|
313
|
5sklA |
Crystal structure of human phosphodiesterase 10 in complex with n-(6-cyano-2-phenylimidazo[1,2-a]pyridin-7-yl)-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide |
